Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | TNF | P01375 | 1/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | VDR | P11473 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10542563 | 0.82 | ALDH1A1 (0.41) | ALDH1A1CYP1A2CYP2C9GAAPOLB | |
| SCHEMBL29565442 | 0.81 | ALDH1A1 (0.46) | ALDH1A1CYP1A2CYP2C9GAACA12 | |
| SCHEMBL9425523 | 0.81 | ALDH1A1 (0.46) | ALDH1A1CYP1A2CYP2C9GAACA12 | |
| SCHEMBL14698753 | 0.80 | ALDH1A1 (0.41) | ALDH1A1CYP1A2CYP2C9GAAKMT2A | |
| SCHEMBL9669589 | 0.80 | ALDH1A1 (0.41) | ALDH1A1CYP1A2CYP2C9GAACA12 | |
| SCHEMBL9143592 | 0.79 | ALDH1A1 (0.41) | ALDH1A1CYP1A2CYP2C9GAACA12 | |
| SCHEMBL30660870 | 0.77 | ALDH1A1 (0.40) | ALDH1A1CYP1A2CYP2C9GAACA12 | |
| SCHEMBL10851006 | 0.77 | ALDH1A1 (0.40) | ALDH1A1CYP1A2CYP2C9GAACA12 | |
| SCHEMBL14587496 | 0.75 | CA12 (0.44) | ALDH1A1CYP1A2CYP2C9GAACA12 | |
| SCHEMBL7850554 | 0.75 | GAA (0.47) | ALDH1A1CYP1A2CYP2C9GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11267826-B2 | Penicillin-binding protein inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2022-03-08 | — | — | US | disclosed |
| EP-3630783-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | Venatorx Pharmaceuticals, Inc. (US) | 2020-04-08 | — | — | EP | disclosed |
| US-20200102331-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-04-02 | — | — | US | disclosed |
| US-20200102331-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-04-02 | — | — | US | disclosed |
| WO-2018218154-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | VenatoRx Pharmaceuticals, Inc. (US) | 2018-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11267826-B2 | Penicillin-binding protein inhibitors | PEPD, BPGM, EBPL | ALDH1A1 2794/4885CYP1A2 3212/4885CYP2C9 2818/4885 |
| US-20200102331-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | PEPD, BPGM, EBPL | ALDH1A1 2794/4885CYP1A2 3212/4885CYP2C9 2818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.